🧬 MSI-H Cancer Research

Microsatellite Instability-High (MSI-H) represents a significant breakthrough in cancer biomarker research, offering new hope for patients across multiple cancer types. MSI-H occurs when tumors have deficient DNA mismatch repair (MMR) mechanisms, leading to a high mutation burden that can make cancer cells more recognizable to the immune system. This distinctive molecular characteristic has emerged as a powerful predictor of immunotherapy response, particularly with checkpoint inhibitor treatments. Researchers have discovered that patients with MSI-H tumors often experience better outcomes with immune-based therapies compared to those with microsatellite stable (MSS) cancers, making this biomarker invaluable for treatment planning and personalized medicine approaches.

The clinical significance of MSI-H testing has grown considerably as oncologists seek to identify which patients are most likely to benefit from immunotherapy. Unlike traditional biomarkers tied to specific cancer types, MSI-H status can be present across diverse malignancies including colorectal cancer, endometrial cancer, gastric cancer, and others. This tumor-agnostic approach has transformed how clinicians think about cancer treatment, allowing them to match patients with the most effective therapies based on molecular characteristics rather than cancer location alone. Regulatory agencies have recognized this importance, with MSI-H testing becoming increasingly standard in cancer diagnostics.

This page brings together the latest peer-reviewed research on MSI-H as a cancer biomarker and diagnostic tool. You'll find comprehensive information about how MSI-H testing works, its role in predicting immunotherapy response, emerging clinical applications, and ongoing studies exploring new treatment combinations. Whether you're a patient seeking to understand your diagnosis, a caregiver supporting a loved one, or someone interested in cancer research advances, these articles represent the cutting-edge science currently shaping MSI-H cancer treatment strategies.